Why the study?
Does D6PV lower plasma triglycerides in preclinical models?
Does D6PV lower plasma triglycerides in preclinical models?
D6PV demonstrates potential as a treatment for hypertriglyceridemia by acting as a dual apoC-II mimetic and apoC-III antagonist with favorable pharmacokinetics in preclinical models.
Supports D6PV advancement to first-in-human HTG trials; leaves open clinical efficacy and safety.
) mice, confirming that it can also act independently of LPL. D6PV displayed good subcutaneous bioavailability of about 80% in nonhuman primates. Because it binds to high-density lipoproteins, which serve as a long-term reservoir, it also has an extended terminal half-life (42 to 50 hours) in nonhuman primates. In summary, D6PV decreases plasma TG by acting as a dual apoC-II mimetic and apoC-III antagonist, thereby demonstrating its potential as a treatment for HTG.
No takes yet. Share an insight, caveat, or question.
Wolska et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: